Alzinova AB
0.43
SEK
+0.00
(+0.82%)
ISIN
SE0007413455
Return %
Stock
S&P 500
1Y
-66.42
14.20
3Y
-76.09
81.12
5Y
-91.84
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Tord Labuda
- Full Time Employees
- 7
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- GoCo House Mölndal VG Sweden 431 53
- IPO Date
- Nov 25, 2015
- Website
- alzinova.com
- Similar Companies
- Business
- Alzinova AB (publ) (ALZ.ST) is a Swedish clinical-stage biopharmaceutical company focused on developing disease-modifying immunotherapies targeting neurotoxic amyloid-beta (Aβ) oligomers for the treatment of Alzheimer's disease; its lead product candidate, ALZ-101, comprises an active therapeutic vaccine in phase 1b clinical development that stimulates production of specific antibodies against toxic Aβ oligomers, demonstrating favorable safety, tolerability, high immune response rates, and dose-dependent antibody increases in patients with early Alzheimer's; ALZ-201 consists of a monoclonal antibody in preclinical development with high specificity for Aβ42 oligomers, lacking affinity for monomers, fibrils, or plaques, and exhibiting potential best-in-class efficacy and safety profiles in preclinical models; the proprietary AβCC peptide™ technology underpins both programs and enables precise targeting of disease-causing oligomers implicated in Alzheimer's onset and progression. Founded in 2011 and headquartered in Mölndal, Sweden, the company operates primarily in the biotechnology sector, serving global markets for neurodegenerative treatments through a business model emphasizing clinical documentation, regulatory preparation, and strategic partnering for commercialization. Recent developments include release of GMP drug substance for ALZ-101's phase 2 trial produced by Polypeptide Laboratories in 2025 with ongoing process optimization; engagement of a US investment bank in 2024 to accelerate partnering for commercialization; a non-binding letter of intent in December 2025 with a Saudi Arabian healthcare provider for potential phase 2 trial conduct, regulatory support, co-development, investment, and commercialization of ALZ-101 and ALZ-201; and a December 2025 memorandum of understanding advancing commercial partnership structures in the region.